A Sting in the Tale of Th2 Immunity  by Gutierrez, Dario A. & Rodewald, Hans-Reimer
Immunity
PreviewsA Sting in the Tale of Th2 ImmunityDario A. Gutierrez1 and Hans-Reimer Rodewald1,*
1Division of Cellular Immunology, German Cancer Research Center, D-69120 Heidelberg, Germany
*Correspondence: hr.rodewald@dkfz.de
http://dx.doi.org/10.1016/j.immuni.2013.10.015
Allergies are widely considered misguided Th2 cell responses. In this issue, Palm et al. (2013) and Marichal
et al. (2013) show that mice mount anti-venom Th2 cell responses that share components of the ‘‘allergic’’
response but confer protection.Common thinking holds that type 2
immunity, IgE, and downstream effector
cells, such as mast cells and basophils,
have evolved to protect against parasitic
infections, e.g., by helminths and ticks.
Components of this immune machinery
can also be activated by noninfectious
allergens that include structurally diverse
plant-, parasite-, or food-derived prod-
ucts or by environmental or synthetic
chemical compounds to drive allergic re-
sponses, including anaphylaxis. Because
the ‘‘purpose’’ of allergy appears to be
elusive, allergies are widely considered
misguided T helper type 2 (Th2) cell
responses or ‘‘a price we have to
pay’’ for sensitive and efficient immunity
against certain parasites (Artis et al.,
2012).
In the real world, allergens can also be
toxins (e.g., trimellitic anhydride). Margie
Profet proposed in 1991 that the function
of allergy is immunological defense
against toxins (Profet, 1991). This ‘‘toxin
hypothesis’’ was recently expanded to-
ward a broader model of intentional host
defense against noninfectious noxious
environmental factors, including venoms
and hematophagous fluids, noxious
xenobiotics, and irritants (Palm et al.,
2012), although these ideas are controver-
sial (Artis et al., 2012).Marichal et al. (2013)
and Palm et al. (2013) now report protec-
tive rather than allergic immune responses
in mice repeatedly challenged by bee
venom or its components.
Palm et al. found that primary immuni-
zation of mice with whole bee venom,
or phospholipase A2 (PLA2), an enzyme
contained in bee venom, induced a
type 2 response characterized by
interleukin-4 (IL-4)-expressing CD4+
T cells, IL-5 secretion by type 2 innate
lymphocytes (ILC2), IL-5-driven eosino-
philia, T cell secretion of IL-4 and 13
upon restimulation in vitro, and elevatedconcentrations of serum IgG1 and IgE.
Confirming earlier work, cleavage of
membrane phospholipids by PLA2 was
sufficient to initiate the response. Analysis
of several downstream reaction products
revealed that lysophosphatidylcholine
(LPC) promoted a Th2 cell response,
potentially by acting as a tissue-damag-
ing detergent. PLA2 is also detected in a
variety of snake venoms, suggesting that
PLA2 alerts the immune system to the
presence of a toxin and induces a Th2
cell response. The link between toxin-
catalyzed tissue damage and the initiation
of a Th2-cell-type response is probably
triggered by the release of IL-33 from
dying cells and by stimulation of IL-33 re-
ceptor (ST2)-expressing T cells and ILC2
cells. The immunized mice also devel-
oped increased serum levels of venom-
specific IgG1 and IgE.
Both Palm et al. and Marichal et al.
found that mice immunized with low
doses of venom were later protected
when rechallenged with higher doses,
reminiscent of a classical adaptive mem-
ory response. Furthermore, mice lacking
B cells, the high-affinity IgE receptor a
chain, FcεRIa, the common FcεRIg
chain, or IgE were poorly protected,
providing strong evidence that IgE bind-
ing to FcεRI largely mediates protection
against bee venom in immunized mice.
Marichal et al., who elicited protection
by subcutaneous venom injections,
found that protection was transferred to
naive mice receiving IgE-containing, but
not IgE-depleted, serum from immunized
animals. In contrast, Palm et al., who
immunized mice intraperitoneally, were
unable to provide passive immunization
to naive animals by serum transfer,
possibly because of lower amounts of
IgE. Beyond a requirement for B cells,
IgE, and FcεRI, little is known about the
protective effector mechanisms andImmunity 39, Nwhich elements of the elicited Th2 cell
immunity are operating. Marichal et al.
examined a potential role for mast cells
in the IgE-mediated adaptive memory
response, but these experiments are
confounded by the fact that mast cells
already play a role in the immediate
innate anti-venom response (Metz et al.,
2006) by hydrolysis of the receptor-
binding site in the toxin (Schneider
et al., 2007), and hence their absence
during both priming and challenge
phases precludes conclusive analyses.
Elucidation of the possible role of mast
cells and other FcεRI-bearing cells in
adaptive protection will require further
work. Finally, the studies showed similar
results with venoms from Western
Diamond Back rattlesnake (Crotalux
atrox), Northern Copperhead (Agkis-
trodon contortrix mokasen), Eastern
Diamonback rattlesnake (Crotalus atrox),
and Russell’s viper (Daboia russelli).
Up to this point, all findings are consis-
tent with a classical adaptive Th2 cell
response. However, unlike the anaphy-
laxis that develops in some humans
repeatedly stung by bees (Figure 1, left
arm), mice were not affected by
hypersensitivity upon secondary venom
challenge. In mice, bee venom induced
a Th2 cell response leading to protec-
tion (Figure 1, middle arm). This outcome
resembled a Th2 cell response against
parasites rather than an allergic Th2 cell
response. Although it is remarkable that
adaptive immunity leads to protection
against toxins, is the underlying response
genuinely a Th2 cell response? The
involvement of Th2 cells, Th2 cytokines,
ILC2, and IgE suggests that the answer
to this question is ‘‘yes,’’ but it is not clear
whether these components of Th2-cell-
mediated immunity are linked in the
context of exposure to venom toxin.
Palm et al. found that the Th2-cell-typeovember 14, 2013 ª2013 Elsevier Inc. 803
Figure 1. Th2 Cell Immunity, IgE-Mediated Anaphylaxis, and IgE-Mediated Protection
against Venoms
IgE is the key effector immunoglobulin class that drives allergy and anaphylaxis (left arm). In this issue of
Immunity, Marichal et al. (2013) and Palm et al. (2013) show that IgE can protect mice against venoms
(middle arm). It is not clear how IgE mediates fundamentally opposing endpoints of protection versus
allergy. This decisionmight be influenced by factors including dose of stimulus, species-specific immuno-
reactivity, tissue context (e.g., site of sting or contact with allergen), or the pathophysiological context,
which might vastly differ between toxins and innocuous allergens. If the initial triggers of the Th2 cell
response and the response itself are indistinguishable during allergy and protection, it is unclear how
FcεRI-expressing effector cells, such as mast cells and basophils, can either provide protection against
toxins or contribute to allergic diseases. Pathways leading to IgE production, which can be induced by
allergens, toxins, and parasites or be promoted by perturbed tissue homeostasis (tissue stress), might
all arise from the classical Th2-cell-mediated pathway (left and middle arms). However, alternative, less
classical routes to IgE production have been reported and might contribute to IgE production in response
to toxins and tissue damage (right arm).
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IL-33 receptor, ST2, and MyD88, which
transmits the ST2 signal in the cell.
Furthermore, the response was TLR- (at
least 2, 4, and 9), and IL-1-receptor-
independent. Unexpectedly, however,
upon reimmunization 21 days after prim-
ing, ST2-deficient mice showed normal
Th2 cell polarization and IgE production
compared to that in wild-type mice.
Moreover, MyD88-deficient mice were
protected similarly to wild-type mice
from a later PLA2 challenge. This indi-
cates a possible disconnect between
the Th2 response and IgE production
and suggests that the IgE response is
either altogether Th2 independent or
that the IgE response is Th2 dependent
but that this Th2 cell response is ST2
independent.
IgE can also be generated via non-
classical routes; this has been noted for
IgE produced during a gd T-cell-mediated
surveillance response in the context of
stressed skin epithelium (Strid et al.,
2011) and for natural, cognate T-cell-
help-independent IgE that lacks depen-
dence on germinal centers. In the latter804 Immunity 39, November 14, 2013 ª2013case, IgE was devoid of significant
somatic mutations (McCoy et al., 2006)
(Figure 1, right arm). IgE production
upon Rae1-induced stress in the skin is
also MyD88 independent (Strid et al.,
2011), akin to the scenario found for the
response to PLA2 or venom. It is therefore
not clear whether bee venom induces
a genuine Th2-cell-type response,
including key steps of cognate T-B cell
help, T cell-derived IL-4-promoting
class-switch recombination, and affinity
maturation of Vh regions in IgE+ B cells
in germinal centers. It would be inter-
esting to identify functionally relevant
source(s) of IL-4, which could be T cells
but also other cell types, during the
course of venom immunizations. Further
analyses of IgE repertoires and develop-
ment of B-cell-secreting IgE under condi-
tions of protective (toxins, parasites,
tissue stress) versus allergic Th2 cell-
mediated immunity are required for the
elucidation of classical (via Th2 cells) or
nonclassical pathways to IgE. Because
some of the conditions studied by Palm
et al. andMarichal et al. might boost over-
all IgE production, not all of which wouldElsevier Inc.be antigen specific, it is important
to determine ratios of antigen-specific
versus nonspecific IgE.
Both studies applied ‘‘natural doses’’ of
venom that amount to the equivalent of
one or few bee stings per mouse. Obvi-
ously, a bee is much smaller in compari-
son to a human than to a mouse, and
the given dose is approximately 3,000-
fold lower for bee-stung humans. If the
antigen dose was the determining factor
that ‘‘guided’’ Th2 cell responses into
either protective (bee-stung mouse) or
allergic (bee-stung human) outcomes, it
should be possible to render mice sus-
ceptible by immunizing them with low
doses of venom. Palm et al. addressed
this point experimentally and found that
lower doses of venom caused protection
to decline with no evidence for sensitiza-
tion. Thus, mice might lack the capacity
to develop hypersensitivity reactions to
bee venom. This contrasts with data that
more than a century ago showed that
initial exposure of dogs to a toxin led to
rapid death by anaphylaxis upon rechal-
lenge (Portier and Richet, 1902). These
paradoxical results from different species
raise several questions. Do toxins have
different immunological effects on
different species, each reflecting the spe-
cies’ natural habitats? Are dogs and
humans more prone to venom-induced
hypersensitivity and mice more prone to
protection? In addition to questions
related to antigen dose and species, it
will be important to determine whether
outcomes (protection versus allergic
sensitization) depend on tissue context
and toxin- and/or allergen-induced path-
ophysiology (Figure 1). Finally, for pre-
vention of allergy and other IgE-related
immunopathology, and to achieve Th2
cell-mediated protection, e.g., by vacci-
nation, it will be essential to identify what
determines the fundamentally opposing
outcomes that occur downstream of IgE
by the action of FcεRI-bearing cells.
REFERENCES
Artis, D., Maizels, R.M., and Finkelman, F.D.
(2012). Nature 484, 458–459.
Marichal, T., Starkl, P., Reber, L.L., Kalesnikoff, J.,
Oettgen, H.C., Tsai, M., and Metz, M. (2013).
Immunity 39, this issue, 963–975.
McCoy, K.D., Harris, N.L., Diener, P., Hatak, S.,
Odermatt, B., Hangartner, L., Senn, B.M., Mars-
land, B.J., Geuking, M.B., Hengartner, H., et al.
(2006). Immunity 24, 329–339.
Immunity
PreviewsMetz, M., Piliponsky, A.M., Chen, C.C., Lammel,
V., Abrink, M., Pejler, G., Tsai, M., and Galli, S.J.
(2006). Science 313, 526–530.Palm, N.W., Rosenstein, R.K., and Medzhitov, R.
(2012). Nature 484, 465–472.Palm, N.W., Rosenstein, R.K., Yu, S., Schenten,
D.D., Florsheim, E., and Medzhitov, R. (2013).
Immunity 39, this issue, 976–985.
Portier, P., and Richet, C. (1902). C. R. Soc. Biol
54, 170.
Profet, M. (1991). Q. Rev. Biol. 66, 23–62.Immunity 39, NSchneider, L.A., Schlenner, S.M., Feyerabend,
T.B., Wunderlin, M., and Rodewald, H.R. (2007).
J. Exp. Med. 204, 2629–2639.
Strid, J., Sobolev, O., Zafirova, B., Polic, B.,
and Hayday, A. (2011). Science 334, 1293–
1297.ovember 14, 2013 ª2013 Elsevier Inc. 805
